Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Renal Cell × tremelimumab × Clear all

Phase

Phase 2 3 Phase 1 3 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 4 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Small Cell Lung Carcinoma 2 Liver Neoplasms 2 Urothelial Cancer 1 Recurrence 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Renal Cell 1 Carcinoma 1

Interventions

Sunitinib 17 Nivolumab 13 pembrolizumab 10 Sorafenib 10 pazopanib 9 cabozantinib 9 Interferon-alpha 9 Everolimus 8 Ipilimumab 7 Bevacizumab 7 belzutifan 6 aldesleukin 6 lenvatinib 5 Magnetic Resonance Spectroscopy 5 Axitinib 5 atezolizumab 4 temsirolimus 3 Radiosurgery 3 Nephrectomy 3 Interferon alpha-2 3 tivozanib 2 durvalumab 2 avelumab 2 Specimen Handling 2 Saline Solution 2 Interleukin-2 2 G250 monoclonal antibody 2 Fluorouracil 2 Chemotherapy, Adjuvant 2 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03288532 2020-09-07

RAMPART

University College, London

Phase 3 Recruiting

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡